Cancer Immunotherapy: Make Way for CAR NK
- PMID: 32086314
- DOI: 10.1158/2159-8290.CD-ND2020-004
Cancer Immunotherapy: Make Way for CAR NK
Abstract
Having shown preclinical promise, the first clinical data are now in on natural killer cells equipped with a chimeric antigen receptor targeting CD19. Albeit in a small number of patients so far, the experimental immunotherapy has elicited a high response rate with little to no toxicity.
©2020 American Association for Cancer Research.
Comment on
-
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607. N Engl J Med. 2020. PMID: 32023374 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical